Talaris Therapeutics is a late-stage cell therapy company developing an innovative method for allogeneic hematopoietic stem cell transplantation. Its lead product candidate is FCR001, which is currently being tested in a Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants and FCR001 for severe non-malignant blood, immune, or metabolic disorders.